Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-05-18
1999-01-26
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530331, 562575, 562545, 514 18, A61K 3805
Patent
active
058639020
ABSTRACT:
Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 -(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; RB is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.
REFERENCES:
patent: 4044126 (1977-08-01), Cook et al.
patent: 4364923 (1982-12-01), Cook et al.
patent: 4414209 (1983-11-01), Cook et al.
patent: 4472305 (1984-09-01), Hansen et al.
patent: 4666829 (1987-05-01), Glenner et al.
patent: 4701407 (1987-10-01), Appal
patent: 4840935 (1989-06-01), Wagnon et al.
patent: 5015570 (1991-05-01), Scangos et al.
patent: 5034376 (1991-07-01), Hoover
patent: 5039611 (1991-08-01), Quay et al.
patent: 5039842 (1991-08-01), Chrobaczek et al.
patent: 5081284 (1992-01-01), Higuchi et al.
patent: 5200339 (1993-04-01), Abraham
patent: 5213962 (1993-05-01), van Nostrant et al.
patent: 5218100 (1993-06-01), Muller-Hill et al.
patent: 5223633 (1993-06-01), Hoppe et al.
patent: 5231000 (1993-07-01), Majocha et al.
patent: 5242932 (1993-09-01), Gandy et al.
patent: 5270165 (1993-12-01), van Nostrandt
patent: 5284828 (1994-02-01), Hemmi et al.
patent: 5374623 (1994-12-01), Zimmerman et al.
patent: 5427931 (1995-06-01), Van Nostrand et al.
patent: 5430022 (1995-07-01), Hemmi et al.
patent: 5470833 (1995-11-01), Ishikawa et al.
patent: 5496928 (1996-03-01), Ishikawa et al.
patent: 5538845 (1996-07-01), Knops et al.
patent: 5547841 (1996-08-01), Marrotta et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5604102 (1997-02-01), McConlogue et al.
patent: 5605811 (1997-02-01), Seubert
patent: 5612488 (1997-03-01), McConlogue et al.
patent: 5652092 (1997-07-01), Vitek et al.
patent: 5656477 (1997-08-01), Vitek et al.
patent: 5703209 (1997-12-01), Vitek et al.
patent: 5766846 (1998-06-01), Schlossmacher et al.
patent: 9207068 (1992-04-01), WOX
Anderson et al, "Differential induction of immediate early gene proteins in cultured neurons by .beta.-amnyloid (A .beta.): Association of c-jun with A.beta.-induced apiptosis," J, Neurochem. 65(4):1487-1489 (1995).
Asami-Odaka et al., "Long amyloid .beta.-protein secreted from wild-type human neuroblastoma IMR-32 cells," Biochemistry 34:10272-10278 (1995).
Barry et al., "Protection against mycoplasma infection using expression-library immunization," Nature 377:632-635 (1995).
Checlar, "Processing of the .beta.-amylodid precursor protein and its regulation in Alzheimer's disease," J. Neurochem. 65(4):1431-1444 (1995).
Lannfelt et al., "Decreased cerebrospinal fluid .alpha.-secretase cleaved amyloid precursor protein (APP) separates Alzheimer patients with the Swedish APP.sub.670/671 mutation from non-mutation carriers," Soc. Neurosci. Abstr. 21 (1995).
Le et al, ".beta.-amyloid.sub.1-40 increases expression of .beta.-amyloid precursor protein in neuronal hybrid cells," J. Neurochem, 65 (5):2373-2376 (1995).
Mahdi et al., "Protease nexin/amyloid .beta.-protein precursor inhibits factor Xa in the prothrombinase complex," J. Biol. Chem. 270(40):23468-23474 (1995).
Moss et al., "Peptidometric inhibitors of herpes simplex virus ribonucleotide reductase: A new class of antiviral agents," J. Med. Chem. 38:3617-3623 (1995).
Pike et al., "Amino-terminal deletions enhance aggregation of .beta.-amyloid peptides in vitro," J. Biol. Chem. 270(41):23895-23898 (1995).
Thaisrivongs et al., "Structure-based design of novel HIV protease inhibitors: Carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors," J. Med. Chem. 38 :3624-3637 (1995).
Wang et al., "A novel matrix attachment region DNA binding motif identified using a random phage peptide library," J. Biol. Chem. 270(40):23239-23242 (1995).
Xu et al., "Regulated formation of Goigi secretory vesicles containing Alzheimer's .beta.-amyloid precursor protein," J. Biol. Chem. 270(40):23243-23245 (1995).
Yoshimoto et al., "NACP, the precursor protein of the non-amyloid .beta./A4 protein (A.beta.) component of Alzheimer's disease amyloid, binds A .beta. and Stimulate A.beta. aggregation," Proc. Natl. Acad. Sci. USA 92:9141-9145 (1995).
Angelastro, et al., "Inhibition of Human Neutrophil Elastase with Peptidyl Electrophilic Ketones," J. Med. Chem., 37:4538-4554 (1994).
Angliker, et al., "Inactivation of calpain by peptidyl fluoromethyl ketones," J. Med. Chem., 35:216-220 (1992).
Arner, et al., "1-Chloro-2,4-dinitrobenzene is an Irreversible Inhibitor of Humman Thioredoxin Reductase," J. Biol. Chem., 270(8):3479-3482 (1995).
Bodanszky and Bodanszky, "I. Protecting Groups 5. The tert.Butyloxycarbonyl (Boc) Group," The Practice of Peptide Synthesis, Springer-Verlag, pp. 18-20 (1984). Human Renin Inhibitory Activity," J. Med. Chem., 33:2335-2342 (1990).
Breaux and Bender, "The binding of specific and non-specific aldehyde substrate analogs to .alpha.-chymotrypsin," FEBS Letters, 56(1):81-84 (1975).
Buxbaum, et al., "Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer .beta./A4 amyloid protein precursor," Proc. Natl. Acad. Sci. USA, 89:10075-10078 (1992).
Cai, et al., "Release of excess amyloid .beta. protein from a mutant amyloid .beta. protein precursor," Science, 259:514-516 (1993).
Caporaso, et al., "Chioroquine inhibits intracellular degradation but not secretion of Alzheimer .beta./A4 amyloid precursor protein," Proc. Natl. Acad. Sci. USA, 89:2252-2256 (1992).
Citron, et al., "Mutation of the .beta.-amyloid precursor protein in familial Alzheimer's disease increases .beta.-protein production," Nature, 360:672-674 (1992).
Cooper, et al,. "X-ray Crystallographic Analysis of Inhibition of Endothiapepsin by Cyclohexyl Renin Inhibitors," Biochemistry, 31:8142-8150 (1992).
Crawford, et al., "The design of peptidyldiazomethane inhibitors to distinguish between the cysteine proteinases calpain II, cathepsin L and cathepsin B," J. Biochem., 253:751-758 (1988).
Crawford, "Protein and peptide inhibitors of calpains," Intracellular Calcium-Dependent Proteolysis Chapter 5, pp. 75-89.
Davis, et al., "A double-blind, placebo-controlled multicenter study of tacrine for Alzehimer's disease." New England J. of Med., 327(18):1253-1259 (1992).
De Strooper, et al., "Basolateral Secretion of Amyloid Precursor Protein in Madin-Darby Canine Kidney Cells is Disturbed by Alterations of Intracellular pH and by Introducing a Mutation Associated with Familial Alzheimer's Disease," J. Biol. Chem., 270(8):4058-4065 (1995).
Dess and Martin, "Readily accessible 12-1-5.sup.1 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones," J. Org. Chem., 48:4155-4156 (1983).
Dolle, et al., "Aspartyl .alpha.-((1-Phenyl-3-(trifluoromethyl)-pyrazol-5-yl)oxy)methyl Ketones as Interleukin-1 .beta. Converting Enzyme Inhibitors. Significance of the P.sub.1 and P.sub.3 Amido Nitrogens for Enzyme-Peptide Inhibitor Binding," J. Med. Chem., 37(23):3863-3866 (1994).
Esch, et al., "Cleavage of amyloid .beta. peptide during constitutive processing of its precursor," Science, 24:1122-1124 (1990).
Farlow, et al., "Low cerebrospinal-fluid concentrations of soluble amyloid .beta.-protein precursor in hereditary Alzheimer's disease," Lancet, 340:453-454 (1992).
Figueiredo-Pereira, et al., "Comparision of the effect of calpain inhibitors on two extralysosomal proteinases: The multicatalytic proteinase complex and m-calpain," J. Neurochemistry, 62(5):1989-1994 (1994).
Figueiredo-Pereira, et al., "A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuro
Albrecht Elisabeth
McDonald Ian A.
Munoz Benito
Lukton David
Seidman Stephanie L.
SIBIA Neurosciences Inc.
Tsang Cecilia J.
LandOfFree
Methods of treating neurodegenerative disorders using protease i does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating neurodegenerative disorders using protease i, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating neurodegenerative disorders using protease i will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1450525